Gilead Sciences ((GILD)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC). The study aims to evaluate the efficacy of GS-1427 in achieving a clinical response in patients with moderate to severe ulcerative colitis by comparing it to a placebo over a 12-week period.
The intervention being tested is GS-1427, an oral drug intended to treat ulcerative colitis. The study includes different doses of GS-1427 and a placebo for comparison purposes.
This interventional study is randomized and follows a sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations, with the primary aim of evaluating treatment efficacy.
The study began on February 16, 2024, with primary completion expected by 2025. The latest update was submitted on August 26, 2025, indicating ongoing recruitment.
The study’s progress could influence Gilead Sciences’ stock performance positively if results demonstrate GS-1427’s efficacy, potentially boosting investor confidence. The competitive landscape in ulcerative colitis treatments could also impact market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.